# US 2022/0031669 A1 · Compositions for Broad Spectrum Topical Antimicrobials

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031669 A1
- Document ID: US20220031669A1
- Status: Published application
- Kind: A1
- Application number: 17/389,259
- Filed: 2021-07-29
- Published: 2022-02-03
- Earliest claimed: 2020-07-30
- Inventors: Allen Gene HIRSH; Cynthia S. Ricard
- Web page: https://patentgrep.com/patent/US20220031669A1

## CPC

- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0043: {Nose}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/16: Amides, e.g. hydroxamic acids
- A61K 31/166: having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A61K 31/396: having three-membered rings, e.g. aziridine
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4174: Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 31/727: Heparin; Heparan
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

In response to the threat of global pandemics and bacterial species becoming increasingly resistant to antibiotic attack, this invention provides systems and methods for reducing the infectivity of bacteria and viruses in the human body by introducing onto the human body or into the human body or onto personal protective equipment or any combination thereof aqueous solutions containing a combination of solutes that simultaneously chemically modify bacterial and viral proteins so as to disrupt their normal function and disrupt the physical integrity of bacterial and viral lipid membranes by providing destabilizing pH, disulfide bond reduction capability, lipid membrane disruption (detergent) capability, hyperosmotic stress and interference with the binding of viral or bacterial proteins to cellular surface proteins.

## Claims

### Claim 1

1) An aqueous solution consisting of at least one buffering component creating a solution pH between pH 2 and pH 10 and at least one disulfide bond reducing component capable of reducing the disulfide bonds of proteins and at least one detergent component capable of degrading the integrity of the lipid membranes of bacteria and/or viruses.

### Claim 2 (depends on 1)

2) The composition of claim 1 wherein each of the components is present in a concentration from 10-6 molar to 1 molar.

### Claim 3 (depends on 1)

3) The composition of claim 1 wherein each of the buffering components contains at least one functionality selected from the group consisting of amino, amido, imino, imido, carboxylic, sulfonic, phosphoric and phosphonic

### Claim 4 (depends on 1)

4) The composition of claim 1 wherein at least one of the disulfide bond reducing agents contains at least one sulfhydryl functionality.

### Claim 5 (depends on 1)

5) The composition of claim 1 wherein at least one of the detergent components contains at least one functionality selected from the
group consisting of amino, amido, imino, imido, quaternary ammonium, carboxylic, sulfonic, sulfate, phosphoric and phosphonic.

### Claim 6 (depends on 1)

6) The composition of claim 1 wherein the least one of the three aqueous solutes are from a group of compounds comprising sodium bicarbonate, benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimonium, cetrimide, dofanium chloride, tetraethylammonium bromide, didecyldimethylammonium chloride, domiphen bromide, acetylcysteine, glutathione, dithiobutylamine and human thioreductase.

### Claim 7 (depends on 1)

7) The composition of claim 1 applied to human nasopharyngeal cavities or epidermal wounds as an aerosol and/or lavage and and/or topical application.

### Claim 8 (depends on 1)

8) The composition of claim 1 applied to protective masks covering the mouth and nose.

### Claim 9

9) An aqueous solution consisting of at least one buffering component creating a solution pH between pH 2 and pH 10 and at least one disulfide bond reducing component capable of reducing the disulfide bonds of proteins and at least one detergent component capable of degrading the integrity of the lipid membranes of bacteria and/or viruses and at least one component that interferes with binding of bacterial and/or viral proteins to proteins on the surface of mammalian cells.

### Claim 10 (depends on 9)

10) The composition of claim 9 wherein each of the components is present in a concentration from 10-9 molar to 1 molar.

### Claim 11 (depends on 9)

11) The composition of claim 9 wherein each of the buffering components contains at least one functionality selected from the group consisting of amino, amido, imino, imido, carboxylic, sulfonic, phosphoric and phosphonic

### Claim 12 (depends on 9)

12) The composition of claim 9 wherein at least one of the disulfide bond reducing agents contains at least one sulfhydryl functionality.

### Claim 13 (depends on 9)

13) The composition of claim 9 wherein at least one of the detergent components contains at least one functionality selected from the group consisting of amino, amido, imino, imido, quaternary ammonium, carboxylic, sulfonic, sulfate, phosphoric and phosphonic.

### Claim 14 (depends on 9)

14) The composition of claim 9 wherein the least one of the three aqueous solutes are from a group of compounds comprising sodium bicarbonate, benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimonium, cetrimide, dofanium chloride, tetraethylammonium bromide, didecyldimethylammonium chloride, domiphen bromide, acetylcysteine, glutathione, dithiobutylamine and human thioreductase.

### Claim 15 (depends on 9)

15) The composition of claim 9 applied to human nasopharyngeal cavities or epidermal wounds as an aerosol and/or lavage and and/or topical application

### Claim 16 (depends on 9)

16) The composition of claim 9 applied to protective masks covering the mouth and nose.

### Claim 17 (depends on 9)

17) The composition of claim 9 wherein the at least one component capable of blocking the binding of viral proteins to cellular proteins are from a group of compounds comprising ritonavir, niclosamide, erythromycin, clarithromycin ,azithromycin, heparin, ivermectin, fidaxomycin, DX600 [amino acid sequence of Ac-GDYSHCSPLRYYPWWKCTYPDPEGGG-NH2], MLN-4760 [(S,S)-2-(1-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid, 2(S)-(1(S)-Carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)-ethylamino)-4-methylpentanoic acid], N-(2-aminoethyl)-1 aziridine-ethanamine,
TAPI-2 [N-(R)-(2-(Hydroxyaminocarbonyl)methyl)-4-methylpentanoyl-L-t-butyl-glycine-L-alanine 2-aminoethyl amide], Emodin [6-methyl-1,3,8-trihydroxyanthraquinone], Resveratrol [trans-3,5,4′-trihydroxystilbene]

### Claim 18

18) An aqueous solution consisting of at least one buffering component creating a solution pH between pH 2 and pH 10 and at least one disulfide bond reducing component capable of reducing the disulfide bonds of proteins and at least one detergent
component capable of degrading the integrity of the lipid membranes of bacteria and/or viruses and at least one component that interferes with binding of bacterial and/or viral proteins to proteins on the surface of mammalian cells and at least one set of enzymatic components capable of reducing the disulfide bonds of proteins.

### Claim 19 (depends on 18)

19) The composition of claim 18 wherein the at least one component of the set of enzymatic components capable of reducing the disulfide bonds of proteins consists an aqueous solution containing thioredoxin, thioredoxin reductase and reduced nicotinamide adenine dinucleotide phosphate

### Claim 20 (depends on 18)

20) The composition of claim 18 wherein each of the components is present in a concentration from 10-10 molar to 1 molar.

### Claim 21 (depends on 18)

21) The composition of claim 18 wherein each of the buffering components contains at least one functionality selected from the group consisting of amino, amido, imino, imido, carboxylic, sulfonic, phosphoric and phosphonic

### Claim 22 (depends on 18)

22) The composition of claim 18 wherein at least one of the disulfide bond reducing agents contains at least one sulfhydryl functionality.

### Claim 23 (depends on 18)

23) The composition of claim 18 wherein at least one of the detergent components contains at least one functionality selected from the group consisting of amino, amido, imino, imido, quaternary ammonium, carboxylic, sulfonic, sulfate, phosphoric and phosphonic.

### Claim 24 (depends on 18)

24) The composition of claim 18 wherein the least one of the three aqueous solutes are from a group of compounds comprising sodium bicarbonate, benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride, cetalkonium chloride, cetylpyridinium chloride, cetrimonium, cetrimide, dofanium chloride, tetraethylammonium bromide, didecyldimethylammonium chloride, domiphen bromide, acetylcysteine, glutathione, dithiobutylamine and thioreductase.

### Claim 25 (depends on 18)

25) The composition of claim 18 wherein the at least one component capable of blocking the binding of viral proteins to
cellular proteins are from a group of compounds comprising ritonavir, niclosamide,erythromycin, clarithromycin ,azithromycin, heparin, ivermectin, fidaxomycin, and umifenovir
